NovaBay Pharmaceuticals Q2 EPS $(1.27) Misses $(0.55) Estimate, Sales $4.61M Beat $3.67M Estimate
Portfolio Pulse from totan@benzinga.com
NovaBay Pharmaceuticals reported Q2 losses of $1.27 per share, missing the analyst consensus estimate of $0.55 by 130.91%. However, the company's quarterly sales of $4.61 million beat the analyst consensus estimate of $3.67 million by 25.61%. This represents a 51.40% increase over sales from the same period last year.
August 10, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
NovaBay Pharmaceuticals reported a larger than expected Q2 loss but beat sales estimates. This mixed result could lead to uncertainty in the market.
NovaBay's larger than expected loss may negatively impact the stock price, but this could be offset by the better than expected sales. The mixed results could lead to uncertainty among investors, potentially causing volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100